Skip to main content

Table 1 Characteristics of studies included in this systematic review and meta-analysis

From: Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis

Author Country Study period (months) Drug regimen No. of participants Genotype Adverse events (%) Patients with detectable parasitaemia and/or malaria clinical episodes (%) No. of deaths Success rate (95% CI)
Olaosebikan et al., 2015 Nigeria 14 MQAS 90 SS/SC 24 7.78 4 61% (compared to PG)
SPAQ 90 13.8 13.33 0 36% (compared to PG)
PG 90 5.4 21.11 3
Diop et al., 2010 Senegal 6 PL 30 SS 3.33 13.33 0 86.67%
SP 30 3.33 0 0 100%
Nakibuuka et al., 2009 Uganda 5 SP 120 SS 6.6 and 1.6 (vomiting, Pruritus) 14 0 50% (compared to CQ)
CQ 122 11.5 and 1.8 (vomiting, Pruritus) 24.6 0
Eke et al., 2003 Nigeria 9 PL 30 SS Not reported 31 1 69%
PM 36 38.9 0 61%
PG 35 15.6 0 84%
Nwokolo et al., 2001 Nigeria 6 PG 57 SS 19.6 18.2 None 81.80%
MQ 56 31.6 10.8 None 89.20%
Warley et al., 1965 Uganda 21 PL 66 SS NA 31.82 None 68.18
CQ + benzathine penicillin 60 NA 11.67 None 88.33
  1. CQ = Chloroquine, MQ = Mefloquine, MQAS = Mefloquine-artesunate, NA = Not available, PL = Placebo, PG = Proguanil, PM = Pyrimethamine, SP=Sulfadoxine-pyrimethamine, SPAQ = Sulfadoxine pyrimethamine-amodiaquine, SS = homozygous sickle haemoglobin